We tested serum for semiquantitative total IgG to the SARS-CoV-2 spike protein (S) receptor-binding domain with the Roche Elecsys Anti-SARS-CoV-2 S assay (anti-S IgG), qualitative detection of high-affinity antibodies to SARS-CoV-2 nucleocapsid (N) protein (anti-N IgG), and neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains (LabCorp; Burlington, NC; Supplement) (41 (link)). The upper limit of quantitation for anti-S IgG was 2,500 U/mL. All samples were tested for anti-S IgG; only baseline samples were tested for anti-N IgG. Neutralizing antibodies were tested at the pre-V1, post-V2, and post-V3 or end-of-study time points in up to 30 chronologically enrolled participants per cellular therapy cohort and vaccine initiation timing subgroup.
Hill J.A., Martens M.J., Young J.A., Bhavsar K., Kou J., Chen M., Lee L.W., Baluch A., Dhodapkar M.V., Nakamura R., Peyton K., Howard D.S., Ibrahim U., Shahid Z., Armistead P., Westervelt P., McCarty J., McGuirk J., Hamadani M., DeWolf S., Hosszu K., Sharon E., Spahn A., Toor A.A., Waldvogel S., Greenberger L.M., Auletta J.J., Horowitz M.M., Riches M.L, & Perales M.A. (2024). SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101). medRxiv.
Other organizations :
Fred Hutch Cancer Center, University of Washington, Medical College of Wisconsin, University of Minnesota System, Adaptive Biotechnologies (United States), Moffitt Cancer Center, Emory University, City of Hope, Alkermes (Ireland), Atrium Health Wake Forest Baptist, Memorial Sloan Kettering Cancer Center, Jewish Hospital, Barnes-Jewish Hospital, Virginia Commonwealth University, University of Kansas, National Marrow Donor Program, Lehigh Valley Health Network, Leukemia and Lymphoma Society, Nationwide Children's Hospital, Cornell University
Semiquantitative total IgG to the SARS-CoV-2 spike protein (S) receptor-binding domain (anti-S IgG)
Qualitative detection of high-affinity antibodies to SARS-CoV-2 nucleocapsid (N) protein (anti-N IgG)
Neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains
control variables
Time points (pre-V1, post-V2, and post-V3 or end-of-study)
controls
Positive control: Not specified
Negative control: Not specified
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to
get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
